1 Result: Pulmonx
Pulmonx Beats Estimates; Strategic Move Boosts TransCode Therapeutics
October 30th, 2023
Pulmonx Corporation (Nasdaq: LUNG) reported a narrower loss than expected in the third quarter of 2023, posting a loss of $(0.39) per share, surpassing the consensus estimate loss of $(0.43) per share. The company's quarterly sales stood at $17.67 mi. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
February 27th, 2026February 26th, 2026
Treasury Sanctions Nicaraguan Officials Enabling the Murillo-Ortega Dictatorship's Repression
February 26th, 2026Kansas City Storm Names Cecil Stockdale as Head Coach for 2026 NJCP Season
February 26th, 2026
Member Login